
Pentadecapeptide of gastric protection — the most studied local repairer. Individual presentation for targeted recovery protocols.
Ranges cited in research literature. Not a usage recommendation. For research use only.
BPC-157 is a pentadecapeptide — fifteen amino acids, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — corresponding to a fragment of a protein isolated from human gastric juice, the “Body Protection Compound”. It was described in the 1990s by Predrag Sikirić's group at the University of Zagreb, which has since published the vast majority of the available literature. It is stable in gastric juice for more than 24 hours, unusual for a linear peptide, and that stability is part of its original appeal.
No classical receptor has been identified. Mechanisms proposed in animal models include modulation of the nitric oxide system, activation of the FAK–paxillin pathway in fibroblasts, VEGFR2 expression and the organization of angiogenesis, plus interactions with dopaminergic and serotonergic systems in gut and brain. In rodents it has been studied in transected Achilles tendon, medial collateral ligament, crushed muscle, gastric lesions and colitis, with consistent results within that research group.
Human evidence is minimal: the two registered clinical trials (Phase 2, rectal route, inflammatory bowel disease) never published complete results, and there is no efficacy trial in musculoskeletal injury. The World Anti-Doping Agency added it to the Prohibited List in 2022 (S0, non-approved substances), and in 2023 the FDA placed it in category 2 of its bulk-substances list over unresolved safety concerns. The angiogenesis it promotes warrants theoretical caution in tumor contexts. Renova distributes it for research only.
| Class | Synthetic pentadecapeptide derived from the Body Protection Compound (human gastric juice) |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 aa) |
| CAS | 137525-51-0 |
| Origin | University of Zagreb (Sikirić group), 1990s |
| Receptor | Not identified; proposed pathways: nitric oxide, FAK–paxillin, VEGFR2 |
| Stability | Stable in gastric juice > 24 h; water-soluble; good stability reconstituted and refrigerated |
| Regulatory status | Not approved; WADA list S0 (2022); FDA bulk-substances category 2 (2023) |
| Renova presentations | 10 mg and 20 mg vials; also in Wolverine, GLOW and KLOW |
It is a 15-amino-acid fragment of a protein present in human gastric juice, identified by Sikirić's group in Zagreb. Coming from that environment, it keeps its structure in gastric juice for more than a day, whereas most linear peptides degrade in minutes. That stability is what prompted the first studies.
Very little. Two Phase 2 rectal trials in inflammatory bowel disease were registered years ago without full publication of results, and there is no controlled trial in tendon, ligament or muscle. All the musculoskeletal-repair literature is in rodents, mostly from a single research group.
Yes. It has been on the World Anti-Doping Agency list since 2022, under section S0 (substances without regulatory approval). In 2023 the FDA also placed it in category 2 of its bulk-substances list, the one for compounds with unresolved safety concerns.
Because in animal models they act on different planes: BPC-157 has mostly been studied as a local repair agent (tendon, mucosa), whereas thymosin β4 mobilizes cells and promotes angiogenesis systemically. The combination, which we offer as the Wolverine Stack, has no studies of its own; the rationale is complementary, not demonstrated.
Related reading: BPC-157: Mechanism, Published Studies and Recovery Applications · Wolverine Stack: BPC-157 + TB-500 Recovery Synergy · Peptide Stacking: Synergy, Sequencing, and Combinations · HHS and peptide compounding in the U.S.: the October 2026 policy and its 10 conditions
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Zones: Santo Domingo · Santiago · Punta Cana · La Romana
Delivery in Santo Domingo in about 2–4 business hours and nationwide in about 6–12 business hours by courier with tracking (RD$400). Reconstituted compounds travel cold-chain (2–8°C) in thermal packaging.
Yes — the BPC-157 certificate of analysis (Janoshik Analytical, HPLC + mass spectrometry) is published at renovapeptides.do/en/coa/#coa-bpc-157, verifiable by test number.
Orders are confirmed over WhatsApp. Payment: Payment Link (PayPal — card, Apple Pay or Venmo), bank transfer, or pay on delivery in Santo Domingo (cash or transfer on receipt).
There is no minimum order. Automatic cart discounts: same-product volume (3+ units 15%, 5+ 25%, 10+ 40%) and Mix & Match across different products (3+ items 10%, 5+ 15%, 7+ 20%; not applicable to Retatrutide or Tirzepatide). The better of the two applies per product; bacteriostatic water is excluded and promo codes can't be combined.
📖 Full guide: BPC-157: Mechanism, Published Studies and Recovery Applications
Your cart is empty